Skip to main content
SpringerLink
Log in

AR-V7 – ein neuer prädiktiver und prognostischer Biomarker

Therapieindividualisierung beim kastrationsresistenten Prostatakarzinom

AR-V7 – a novel predictive and prognostic biomarker

Individualized therapy for castration-resistant prostate cancer

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Tannock IF et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512

    Article  CAS  PubMed  Google Scholar 

  2. Amsberg G von et al (2014) Current treatment concepts for castration resistant prostate cancer. Dtsch Med Wochenschr 139(41):2086–2090

    Article  Google Scholar 

  3. Antonarakis ES (2015) Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key? Expert Rev Anticancer Ther 15(2):143–145

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. O’Donnell A et al (2004) Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90(12):2317–2325

    Google Scholar 

  5. Tran C et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787–790

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Zhang T et al (2015) Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. Expert Opin Pharmacother 16(4):473–485

    Article  CAS  PubMed  Google Scholar 

  7. Soest RJ van et al (2015) Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur Urol 67(6):981–985

    Article  PubMed  Google Scholar 

  8. Al Nakouzi N et al (2015) Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 68(2):228–235

    Article  Google Scholar 

  9. Antonarakis ES, Lu C, Chen Y et al (2015) AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 33(suppl 7):abstr 138

    Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. C. Oing gibt an, dass kein Interessenkonflikt besteht. C. Bokemeyer: Beratertätigkeit und Vorträge: Sanofi. G. von Amsberg: Beratertätigkeit und Vorträge: Astellas; Vorträge: Sanofi.

Der Beitrag enthält keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. II. Medizinische Klinik – Onkologie, Hämatologie und Stammzelltransplantation mit Sektion Pneumologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland

    C. Oing, G. von Amsberg & C. Bokemeyer

Authors
  1. C. Oing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. von Amsberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Bokemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Oing.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oing, C., von Amsberg, G. & Bokemeyer, C. AR-V7 – ein neuer prädiktiver und prognostischer Biomarker. Onkologe 21, 846–847 (2015). https://doi.org/10.1007/s00761-015-3019-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-015-3019-9

Search

Navigation